Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Advancing 6-bromo-7-[11C]methylpurine to clinical use: improved regioselective radiosynthesis, non-clinical toxicity data and human dosimetry estimates

S. Mairinger, M. Jackwerth, O. Soukup, M. Blaickner, C. Decristoforo, L. Nics, J. Pahnke, M. Hacker, M. Zeitlinger, O. Langer

. 2024 ; 9 (1) : 34. [pub] 20240429

Status neindexováno Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24012904

Grantová podpora
882717 Österreichische Forschungsförderungsgesellschaft
327571 Norwegian Research Council (NFR)
8F21002 Ministry of Education, Youth and Sports (MŠMT)

BACKGROUND: 6-Bromo-7-[11C]methylpurine ([11C]BMP) is a radiotracer for positron emission tomography (PET) to measure multidrug resistance-associated protein 1 (MRP1) transport activity in different tissues. Previously reported radiosyntheses of [11C]BMP afforded a mixture of 7- and 9-[11C]methyl regioisomers. To prepare for clinical use, we here report an improved regioselective radiosynthesis of [11C]BMP, the results of a non-clinical toxicity study as well as human dosimetry estimates based on mouse PET data. RESULTS: [11C]BMP was synthesised by regioselective N7-methylation of 6-bromo-7H-purine (prepared under good manufacturing practice) with [11C]methyl triflate in presence of 2,2,6,6-tetramethylpiperidine magnesium chloride in a TRACERlabTM FX2 C synthesis module. [11C]BMP was obtained within a total synthesis time of approximately 43 min in a decay-corrected radiochemical yield of 20.5 ± 5.2%, based on starting [11C]methyl iodide, with a radiochemical purity > 99% and a molar activity at end of synthesis of 197 ± 130 GBq/μmol (n = 28). An extended single-dose toxicity study conducted in male and female Wistar rats under good laboratory practice after single intravenous (i.v.) administration of unlabelled BMP (2 mg/kg body weight) revealed no test item related adverse effects. Human dosimetry estimates, based on dynamic whole-body PET data in female C57BL/6J mice, suggested that an i.v. injected activity amount of 400 MBq of [11C]BMP will deliver an effective dose in the typical range of 11C-labelled radiotracers. CONCLUSIONS: [11C]BMP can be produced in sufficient amounts and acceptable quality for clinical use. Data from the non-clinical safety evaluation showed no adverse effects and suggested that the administration of [11C]BMP will be safe and well tolerated in humans.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24012904
003      
CZ-PrNML
005      
20240726151439.0
007      
ta
008      
240723s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s41181-024-00265-z $2 doi
035    __
$a (PubMed)38683266
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Mairinger, Severin $u Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. severin.mairinger@meduniwien.ac.at $u Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria. severin.mairinger@meduniwien.ac.at $1 https://orcid.org/0000000150949351
245    10
$a Advancing 6-bromo-7-[11C]methylpurine to clinical use: improved regioselective radiosynthesis, non-clinical toxicity data and human dosimetry estimates / $c S. Mairinger, M. Jackwerth, O. Soukup, M. Blaickner, C. Decristoforo, L. Nics, J. Pahnke, M. Hacker, M. Zeitlinger, O. Langer
520    9_
$a BACKGROUND: 6-Bromo-7-[11C]methylpurine ([11C]BMP) is a radiotracer for positron emission tomography (PET) to measure multidrug resistance-associated protein 1 (MRP1) transport activity in different tissues. Previously reported radiosyntheses of [11C]BMP afforded a mixture of 7- and 9-[11C]methyl regioisomers. To prepare for clinical use, we here report an improved regioselective radiosynthesis of [11C]BMP, the results of a non-clinical toxicity study as well as human dosimetry estimates based on mouse PET data. RESULTS: [11C]BMP was synthesised by regioselective N7-methylation of 6-bromo-7H-purine (prepared under good manufacturing practice) with [11C]methyl triflate in presence of 2,2,6,6-tetramethylpiperidine magnesium chloride in a TRACERlabTM FX2 C synthesis module. [11C]BMP was obtained within a total synthesis time of approximately 43 min in a decay-corrected radiochemical yield of 20.5 ± 5.2%, based on starting [11C]methyl iodide, with a radiochemical purity > 99% and a molar activity at end of synthesis of 197 ± 130 GBq/μmol (n = 28). An extended single-dose toxicity study conducted in male and female Wistar rats under good laboratory practice after single intravenous (i.v.) administration of unlabelled BMP (2 mg/kg body weight) revealed no test item related adverse effects. Human dosimetry estimates, based on dynamic whole-body PET data in female C57BL/6J mice, suggested that an i.v. injected activity amount of 400 MBq of [11C]BMP will deliver an effective dose in the typical range of 11C-labelled radiotracers. CONCLUSIONS: [11C]BMP can be produced in sufficient amounts and acceptable quality for clinical use. Data from the non-clinical safety evaluation showed no adverse effects and suggested that the administration of [11C]BMP will be safe and well tolerated in humans.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Jackwerth, Matthias $u Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
700    1_
$a Soukup, Ondřej $u Biomedical Research Center, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Blaickner, Matthias $u Department Computer Science, University of Applied Sciences Technikum Wien, Vienna, Austria
700    1_
$a Decristoforo, Clemens $u Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria
700    1_
$a Nics, Lukas $u Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
700    1_
$a Pahnke, Jens $u Translational Neurodegeneration Research and Neuropathology Lab, Department of Clinical Medicine (KlinMed), Medical Faculty, University of Oslo, Oslo, Norway $u Section of Neuropathology Research, Department of Pathology, Clinics for Laboratory Medicine (KLM), Oslo University Hospital, Oslo, Norway $u Institute of Nutritional Medicine (INUM) and Lübeck Institute of Dermatology (LIED), University of Lübeck and University Medical Center Schleswig-Holstein, Lübeck, Germany $u Department of Pharmacology, Faculty of Medicine, University of Latvia, Rīga, Latvia $u School of Neurobiology, Biochemistry and Biophysics, The Georg S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
700    1_
$a Hacker, Marcus $u Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
700    1_
$a Zeitlinger, Markus $u Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
700    1_
$a Langer, Oliver $u Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria $u Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
773    0_
$w MED00214678 $t EJNMMI radiopharmacy and chemistry $x 2365-421X $g Roč. 9, č. 1 (2024), s. 34
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38683266 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240723 $b ABA008
991    __
$a 20240726151431 $b ABA008
999    __
$a ok $b bmc $g 2125515 $s 1224767
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 9 $c 1 $d 34 $e 20240429 $i 2365-421X $m EJNMMI radiopharmacy and chemistry $n EJNMMI Radiopharm Chem $x MED00214678
GRA    __
$a 882717 $p Österreichische Forschungsförderungsgesellschaft
GRA    __
$a 327571 $p Norwegian Research Council (NFR)
GRA    __
$a 8F21002 $p Ministry of Education, Youth and Sports (MŠMT)
LZP    __
$a Pubmed-20240723

Najít záznam

Citační ukazatele

Možnosti archivace